Patents by Inventor Neville J. Anthony

Neville J. Anthony has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20080275097
    Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R1, R2, R4, R5, R6, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: December 6, 2007
    Publication date: November 6, 2008
    Inventors: Neville J. Anthony, Robert Gomez, Samson M. Jolly, Dai-Shi Su, John Lim
  • Arylsulfonamide derivatives
    Patent number: 7393873
    Abstract: N-aryl arylsulfonamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: July 1, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, John Jin Lim, Dai-shi Su, Michael R. Wood
  • Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
    Patent number: 7332499
    Abstract: N-(Sulfonyloxybiarylmethyl) aminocyclopropanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: February 19, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert Gomez, Samson M. Jolly, John Jin Lim, Dai-shi Su
  • N-biphenylmethyl aminocycloalkanecarboxamide derivatives
    Patent number: 7091380
    Abstract: N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 15, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Sodium salt of an HIV integrase inhibitor
    Patent number: 6924282
    Abstract: A sodium salt of Compound A is disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for preventing or treating HIV infection, for delaying the onset of AIDS, and for treating AIDS.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: August 2, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Wei Xu, John V. Lepore, Amar J. Mahajan
  • Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
    Patent number: 6921759
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: July 26, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa Egbertson, John S. Wai, Linghang Zhuang, Mark Embrey, Jeffrey Y. Melamed, H. Marie Langford, James P. Guare, Thorsten E. Fisher, Samson M. Jolly, Michelle S. Kuo, Debra S. Perlow, Jennifer J. Bennett, Timothy W. Funk
  • N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
    Patent number: 6919343
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: July 19, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
    Patent number: 6919351
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: July 19, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa S. Egbertson, John S. Wai, Jennifer J. Bennett
  • Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
    Patent number: 6841558
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating, or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Jennifer J. Bennett
  • Aza-and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
    Publication number: 20040044207
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating, or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: August 21, 2003
    Publication date: March 4, 2004
    Inventors: Neville J Anthony, Robert P. Gomez, Steven D Young, Jennifer J. Bennett
  • Aza-and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
    Publication number: 20040034221
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: August 21, 2003
    Publication date: February 19, 2004
    Inventors: Neville J Anthony, Robert P. Gomez, Steven D. Young, Melissa S, Egbertson, John S. Wai, Jennifer J. Bennett
  • N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
    Publication number: 20030220375
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Application
    Filed: January 30, 2003
    Publication date: November 27, 2003
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Sodium salt of an HIV integrase inhibitor
    Publication number: 20030119823
    Abstract: A sodium salt of Compound A is disclosed, wherein Compound A is of formula: 1
    Type: Application
    Filed: August 14, 2002
    Publication date: June 26, 2003
    Inventors: Neville J. Anthony, Wei Xu, John V. Lepore, Amar J. Mahajan
  • Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
    Publication number: 20030055071
    Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Application
    Filed: October 10, 2001
    Publication date: March 20, 2003
    Inventors: Neville J. Anthony, Robert P. Gomez, Steven D. Young, Melissa Egbertson, John S. Wai, Linghang Zhuang, Mark Embrey, LeKhanh Tran, Jeffrey Y. Melamed, H. Marie Langford, James P. Guare, Thorsten E. Fisher, Samson M. Jolly, Michelle S. Kuo, Debra S. Perlow, Jennifer J. Bennett, Timothy W. Funk
  • Inhibitors of prenyl-protein transferase
    Patent number: 6358985
    Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Ian M. Bell, Douglas C. Beshore, Terrence M. Ciccarone, S. Jane de Solms, Christopher J. Dinsmore, Gerald E. Stokker
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6248756
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferas (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: June 19, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Christopher Dinsmore, Robert P. Gomez, John H. Hutchinson, John S. Wai, Theresa M. Williams, Ian M. Bell, Mark W. Embrey, Thorsten E. Fisher
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6093737
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: July 25, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Lekhanh O. Tran, Steven D. Young
  • Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
    Patent number: 6080870
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 1, 1998
    Date of Patent: June 27, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, Robert P. Gomez, Gerald E. Stokker, John S. Wai, Theresa M. Williams, Wasyl Halczenko, John H. Hutchinson, Steven D. Young, Kelly M. Solinsky
  • Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
    Patent number: 6063930
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: May 16, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Christopher J Dinsmore, Neville J. Anthony, Gerald E. Stokker, Robert P. Gomez
  • Inhibitors of farnesyl-protein transferase
    Patent number: 6051574
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventor: Neville J. Anthony